Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Ciltyri; Sliwens; SR 46349; SR 46349B; SR 46615A

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Class Fluorobenzenes; Phenols; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Apnoea; Insomnia; Major depressive disorder; Myocardial infarction

Most Recent Events

  • 22 Dec 2009 Discontinued - Preregistration for Insomnia in European Union (PO)
  • 22 Dec 2009 Discontinued - Preregistration for Insomnia in USA (PO)
  • 16 Sep 2009 Sanofi-Aventis receives complete response letter from the US FDA for eplivanserin in Insomnia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top